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ABSTRACT
Introduction: Despite being frequently
diagnosed, there has been very limited study
of efficacious treatments for schizoaffective
disorder. Paliperidone had been approved for
the treatment of schizoaffective disorder, and a
recently completed relapse prevention study of
the use of a once-monthly injectable
paliperidone formulation has also led to an
indication for that preparation to treat
schizoaffective disorder.
Methods: To review the efficacy and tolerability
of paliperidone for schizoaffective disorder, we
conducted a systematic literature search of
studies of paliperidone in the treatment of
schizoaffective disorder, and briefly reviewed
evidence regarding the somewhat controversial
nature of that diagnostic entity.
Results: We located several studies of the use of
paliperidone extended release in the treatment
of schizoaffective disorder, but only one
completed study of the use of paliperidone
palmitate, which demonstrated efficacy in
preventing relapse. Three other studies are
currently recruiting participants. Efficacy and
tolerability were similar to the profile of oral
paliperidone in the treatment of individuals
with schizophrenia. These results were similar
for both individuals treated with paliperidone
palmitate alone, and for those treated with
paliperidone palmitate with adjunctive mood
stabilizers and/or antidepressants. The use of
paliperidone palmitate does not require initial
co-administration of oral paliperidone, has
relatively little risk of drug–drug interactions,
and its pharmacokinetics are favorable for
once-monthly administration, an important
treatment option for individuals with
psychotic disorders, who may often be
non-adherent to effective medication regimens.
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version of this article (doi:10.1007/s40120-015-0030-4)
contains supplementary material, which is available to
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Conclusion: Paliperidone palmitate is an
approved treatment for schizoaffective
disorder, and can be efficacious with or
without commonly employed adjunctive
treatments.
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Schizoaffective disorder has been a
controversial diagnosis. It has long been
recognized that many patients with psychotic
symptoms do not neatly fit into the
Kraepelinian diagnostic dichotomy of what we
now label schizophrenia and bipolar disorder,
but rather present with varying presentations of
mood and psychotic symptoms. In 1933,
Kasinin proposed the term ‘‘schizoaffective
psychosis’’ to designate individuals
prominently displaying both psychotic and
mood symptoms, claiming that those so
diagnosed would have a better prognosis [1].
The ‘‘affective’’ portion of the term
‘‘schizoaffective’’ itself remains something of an
anachronistic misnomer, as aside from the
psychotic symptomatology, there is also a
primary disturbance in mood (a pervasive and
sustained emotional state), not affect per se.
Affect is defined as observable behaviors that
express a current emotional state, which may
fluctuate; in the past, other mood disorders were
also inaccurately labeled ‘‘affective’’ disorders.
Early versions of the Diagnostic and
Statistical Manual of Mental Disorders (DSM)
included this entity using slightly different
terminology, such as ‘‘schizophrenic reaction,
schizoaffective type’’ in DSM-I and
‘‘schizophrenia, schizoaffective type’’ (either
excited or depressed) in DSM-II, but in 1980 in
DSM-III it was named ‘‘schizoaffective disorder,’’
and was the only diagnosis in that edition that
did not employ specific diagnostic criteria. In
DSM-III-R (1987) criteria were introduced,
which required a period of psychosis meeting
criteria for schizophrenia during which mood
symptoms were present for ‘‘more than a brief’’
period of time, and also a period of psychotic
symptoms without mood symptoms of at least
two weeks, to distinguish schizoaffective
disorder from a mood disorder with psychotic
symptoms. DSM-IV (1994) further recognized
two subtypes of schizoaffective disorder:
‘‘depressive type’’ and ‘‘bipolar type,’’ and
DSM-IV-TR (2000) required that the mood
symptoms must be present for ‘‘a substantial
portion’’ of the course of the disorder, without
further quantification.
This vagueness in the diagnostic criteria has
been further compounded by the common
difficulty in obtaining an accurate longitudinal
description of the course of patients’ symptoms.
It is commonly not possible to adequately
establish accurate periods of time for which
prominent mood symptoms have been present
over the course of a patient’s history with and
without delusions and hallucinations, and
verify that such symptoms were not caused by
the use of, or withdrawal from, substances of
abuse, let alone formally decide on the
definition of ‘‘substantial period.’’ Not
surprisingly, therefore, kappa values for
diagnostic agreement have been notably poor:
Hiller et al. [2] reported a kappa of 0.08 using
DSM-III-R criteria for schizoaffective disorder,
and Maj et al. [3] reported a kappa of 0.22 using
DSM-IV criteria, far below the more desirable
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range indicating at least moderate interrater
agreement (0.4–0.6).
Appreciably better kappa values have been
reported using International Classification of
Diseases (ICD)-10 criteria, although that criteria
set is quite similar to that of DSM-IV-TR.
However, a study in Denmark of patients with
hospital discharge diagnoses of schizoaffective
disorder found that none met DSM-IV-TR
criteria and only 10% met ICD-10 criteria [4].
Seeking to improve reliability, DSM-5 (2013)
usefully added the specification that the
symptoms of a major mood episode were
present for the majority of the total duration
of the active and residual portions of the illness,
which is somewhat more specific, although
whether this will appreciably improve
diagnostic reliability and validity must await
future study [5]. Exploring issues regarding the
validity of the diagnosis, a detailed review by
Kantrowitz and Citrome [6] examined possible
differentiating characteristics that would
distinguish schizoaffective disorder from
schizophrenia and bipolar disorder, including
prognosis, genetic linkage studies,
neuropsychological testing and pharmacological
response, finding at best very modest evidence,
although some results of neurophysiological
sensory testing pointed towards some possible
discriminating characteristics. Likewise, a
longitudinal study of first-admission patients
with a diagnosis of schizoaffective disorder did
not generate support for the validity of the
diagnosis of schizoaffective disorder based on
symptom course and outcomes [7].
In fairness, however, it should be noted
that schizophrenia and bipolar disorder
themselves do not admit of neatly separating
genetic findings, with not only numerous
proposed genetic linkages, but with some
that appear to be common for both
schizophrenia and psychotic bipolar disorder
[8]. Moreover, there have been thoughtful
proposals to formulate schizophrenia,
schizoaffective disorder and bipolar disorder
as representing more of a continuous
spectrum, or viewed in a dimensional
approach [9]. Clearly, this is still an enduring
area of controversy; it remains a significant
nosologic challenge for the field’s attempts to
skillfully ‘‘carve Nature at its joints’’.
Given these concerns, one must explain why
we have the diagnostic category of
schizoaffective disorder. Of most relevance is
the fact that this diagnosis is very commonly
used, with an estimated lifetime prevalence of
0.3% [10], that is, a third or more as common as
the diagnosis of schizophrenia, and translating to
about 750,000 adult Americans. It likely serves as
a useful clinical marker for the clinician to
consider the adjunctive use of mood stabilizers
or antidepressants in a given patient, which
indeed is commonly done, although there is
little high-quality evidence available supporting
the efficacy of these adjunctive treatments.
Notably, in 2009, the Food and Drug
Administration (FDA) approved paliperidone for
the treatment of schizoaffective disorder, the first
time that the agency recognized this as a valid
diagnostic entity for a therapeutic indication
[11]. Since that time, when new antipsychotic
agents have been submitted for approval using
studies that enroll both individuals with
schizophrenia and schizoaffective disorder, the
FDA has examined data for those two diagnostic
groups separately. Recently, the FDA expanded
the indication for paliperidone, to include
relapse prevention of schizoaffective disorder
using a long-acting injectable (LAI) formulation
of paliperidone, paliperidone palmitate [12].
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Paliperidone
Paliperidone (trade name Invega; Janssen), the
9-hydroxy active metabolite of risperidone
(trade name Risperdal; Janssen) responsible
for most of the antipsychotic potency of
risperidone, is an antipsychotic medication
that was developed by Janssen
Pharmaceuticals, and was approved by the
FDA in 2006 for the indication of the
treatment of schizophrenia [11]. It is available
in an oral extended-release formulation
(paliperidone ER) that employs two drug layers
and an osmotically active core layer that pushes
the drug out (‘‘OROS,’’ a patented technology),
allowing for slow, more even drug release
supporting convenient once-daily dosing. Like
other second-generation antipsychotics, it is
believed that paliperidone’s antipsychotic
mechanism of action is antagonism at
dopamine D2 receptors and serotonin-2A
receptors in the brain, the latter action also
helping limit some extrapyramidal adverse
effects. Paliperidone is also an antagonist at a1
and a2 adrenergic and H1 histamine receptors,
but, unlike most first-generation antipsychotics,
not at muscarinic cholinergic receptors [13].
Activity at particular receptors informs
expectations for specific adverse effects.
Specifically, blocking dopamine D2 receptors
does dampen down agitation and helps treat
delusions and hallucinations, but, if too
pronounced, may result in the extrapyramidal
side effects of dystonic reactions, parkinsonism,
and tardive dyskinesia, as well as akathisia
(pronounced restlessness in the lower
extremities), and may cause neuroleptic
malignant syndrome. D2 receptor antagonism
also increases serum prolactin levels, which may
interfere with the menstrual cycle or cause
lactation in women, and may cause breast
swelling and interfere with sex drive and
functioning in either sex, with long-term use
potentially decreasing bone density. Blocking
serotonin-2A receptors may help with anxiety,
irritability, insomnia, and mitigate some
extrapyramidal side effects. Alpha1-adrenergic
blocking medications such as prazosin and
doxazosin have use in treating hypertension
and benign prostatic hypertrophy, but are also
prescribed off-label in treating posttraumatic
stress disorder; they may be associated with
adverse effects of postural hypotension and
nasal congestion, as well as priapism and
retrograde ejaculation [14, 15]. Alpha2-blocking
medications such as clonidine and guanfacine
have been used to treat attention-deficit disorder
symptoms, and may be associated with dry
mouth, sedation, dizziness and constipation.
Histamine H1 antagonists treat allergies, but
also can cause sedation and weight gain. As
with many other antipsychotic medications, an
increase in weight may be associated with
glucose intolerance and the development of
diabetes mellitus or a metabolic syndrome.
Knowledge of these other receptor effects is
useful in treating individuals who often have
co-occurring symptoms or disorders, or
heightened sensitivities to particular adverse
effects. Paliperidone does modestly increase the
electrocardiogram QT interval, an issue for
individuals particularly vulnerable to this effect,
and can make certain medication combinations
(such as with citalopram) problematic.
Paliperidone ER (available in 1.5, 3, 6 and
9 mg extended-release tablets) is the marketed
oral formulation, and has a maximum serum
concentration (Cmax) approximately 24 h after a
single dose. It can be taken with or without
food, but it should be noted that it has 28%
absolute oral bioavailability, with area under
the plasma drug concentration–time curve
84 Neurol Ther (2015) 4:81–91
(AUC) increased by 54% when administered
with a standard high-fat/high-caloric meal. The
recommended dose of the tablet is 6 mg/day
(once-daily dosing), with a maximum
recommended daily dose of 12 mg/day;
pharmacokinetics are dose-proportional within
the recommended dose range [11].
The long-acting parenteral form, paliperidone
palmitate, is available in 39, 78, 117, 156 or
234 mg doses of injectable suspension (providing
paliperidone doses equivalent to 25, 50, 75, 100
and 150 mg, respectively). Individuals should
have had some previous exposure to either
risperidone or paliperidone to rule out any
severe intolerance, before beginning long-acting
parenteral treatment. The recommended initial
dosing to treat schizophrenia or schizoaffective
disorder is administering 234 mg on the first day
and 156 mg one week later, both in the deltoid
muscle to facilitate more rapid absorption (and
therefore not require a lead-in period of oral
supplementation). Following this, an appropriate
intramuscular dose should be administered
monthly afterwards, in the deltoid or gluteal
muscle, as preferred, of 39, 78, 156 or 234 mg
(the 39 mg monthly dose was not studied in
patients with schizoaffective disorder).
Paliperidone is metabolized by CYP2D6 and
CYP3A4, but only to a limited extent, and is
mainly excreted renally. Following a single oral
dose, 59% was excreted unchanged in the urine,
and most of the metabolites were also renally
excreted. Because of limited hepatic
metabolism, mild or moderate hepatic
impairment has little effect on dosing
recommendations, and extensive or poor
metabolizer status for CYP2D6 is not
particularly important, although the dose
should be lowered for those with renal
impairment. Dosage adjustment upwards of
paliperidone may be required in the presence
of strong CYP3A4/P-glycoprotein inducers (for
example, carbamazepine, rifampin, St. John’s
wort).
Paliperidone does not substantially inhibit the
CYP450 hepatic enzymes, and is a weak inhibitor
ofP-glycoproteinbutonlyathighconcentrations;
it is therefore also not likely to significantly affect
the metabolism of other drugs.
METHODS
This article does not contain any new studies
withhumanor animal subjects performedby any
of the authors. The analysis in this article is based
on previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Searches were conducted on March 13, 2015
of PubMed, Embase, and Web of Science using
the text words ‘‘paliperidone’’ and
‘‘schizoaffective’’, and ClinicalTrials.gov using
‘‘paliperidone palmitate’’. Both authors
reviewed the results of the searches for
relevance. These searches identified the one
published pivotal relapse prevention study.
Additionally, one brief case report was
identified regarding the combined use of
paliperidone palmitate and olanzapine
pamoate in treatment-resistant schizoaffective
disorder [16]. Another abstract briefly addressed
the subsequently published full report of the
relapse prevention trial. For added context, we
also reviewed some key studies of paliperidone




There have been two acute clinical trials of the
oral formulation paliperidone ER for
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schizoaffective disorder [17, 18]. A pooled
analysis of these two 6-week registration trials
of paliperidone ER for the acute treatment of
individuals aged 18–65 years with
schizoaffective disorder diagnosed using the
Structured Clinical Interview for DSM-IV
Disorders (SCID) included 614 subjects in the
intent-to-treat population; 414 were
randomized to receive paliperidone ER
3–12 mg/day and 200 to receive placebo [19].
Of these, 275 (45%) of subjects had been
receiving adjunctive treatment with mood
stabilizers and/or antidepressants; these
adjunctive medications were continued for
both treatment groups. All enrolled subjects
were experiencing an acute exacerbation of
their psychotic disorder at screening; had a
Positive and Negative Syndrome Scale (PANSS)
score C60 with a score C4 on two or more of the
PANSS items hostility, excitement, tension,
uncooperativeness and poor impulsive control;
had significant mood symptoms as evidenced
by a score C16 on the Young Mania Rating Scale
(YMRS) and/or a score C16 on the Hamilton
Rating Scale for Depression, 21-item
(HAM-D-21).
In one study (ClinicalTrials.gov identifier,
NCT00397033), subjects receiving paliperidone
were randomized to receive 9–12 mg of
paliperidone/day or 3–6 mg of paliperidone/day
(dosed at the higher number, and later reduced if
clinically indicated) [17]. In the other study
(ClinicalTrials.gov identifier, NCT00412373),
those randomized to paliperidone received
6 mg/day to start, but were then flexibly dosed,
as clinically appropriate, in the range of
3–12 mg/day [18]. Both studies stratified
randomization by study center and by whether
the subject was being concurrently treated with
mood stabilizers and/or antidepressants. The
primary efficacy outcome measure for both
studies was the change in the PANSS total score
from baseline to endpoint, and secondary
efficacy measures included changes in the
Clinical Global Impressions of Severity for
Schizoaffective Disorder (CGI-S-SCA), PANSS
factor scores, YMRS, and HAM-D-21 scores [20].
Demographic and clinical characteristics at
baseline were similar for the treatment groups.
Overall, 275 subjects were taking mood
stabilizers and/or antidepressants; 69% of this
group were taking mood stabilizers (principally
valproate) and 59% were taking antidepressants.
Subjects randomized to paliperidone ER
improved significantly more from day 4 to
study endpoint, the placebo-adjusted least
square mean (SE) difference at last observation
carried forward (LOCF) for the PANSS total score
was -7.8 (1.7), with P\0.001, and an effect size
of 0.41; both subgroups with and without
adjunctive mood stabilizer/antidepressant
adjunctive treatment improved significantly
more with paliperidone compared with placebo
treatment. Secondary measures all were
significantly better for the paliperidone
treatment group as well, compared with placebo.
Maintenance (Prevention of Relapse)
A randomized, double-blind, placebo-controlled
study with a 15-month relapse prevention phase
examined the efficacy of monthly intramuscular
injections of paliperidone palmitate compared
with placebo during that phase
(ClinicalTrials.gov identifier, NCT011193153)
[21]. As in the acute studies of paliperidone,
enrollees were diagnosed with schizoaffective
disorder using the SCID interview (DSM-IV,
Clinician Version), and were stratified by study
center and by subjects’ concurrent use of mood
stabilizers or antidepressants or the lack of such
treatment, and by study center in this
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international study. Those who had received
treatment with both mood stabilizers and
antidepressants were excluded from study
participation (this was not a criterion in the
previous acute study), as were individuals who
had begun treatment with mood stabilizers or
antidepressants or had dosage changes in the
30 days prior to screening. Pre-study treatment
with benzodiazepines was also allowed to
continue at a stable dose, and there was some
limited allowance for newly initiating
benzodiazepines or other hypnotics during the
study.
Enrolled subjects were required to be
experiencing an acute exacerbation of
psychotic symptoms at screening, as
evidenced by a score C4 on 3 or more of the
PANSS items: delusions, conceptual
disorganization, hallucinatory behavior,
excitement, suspiciousness/persecution,
hostility, tension, uncooperativeness, and
poor impulse control, and were experiencing
significant mood symptoms, as evidenced by a
YMRS and/or HAM-D-21 score C16. After
enrollment, subjects began a 13-week
open-label lead-in phase during which all
received the two recommended initial doses
of paliperidone 1 week apart (234 mg on Day
1, 156 mg on Day 8) and then flexible-dose
intramuscular paliperidone palmitate
monthly (78–234 mg), followed by a 12-week
stabilization phase during which treatment
continued with the established dose for
each subject. No oral supplementation of
antipsychotics was permitted in this study.
Stabilization criteria included a PANSS total
score B70, and YMRS and HAM-D-21 scores B12.
Those continuing were randomized to
receive either monthly injections of
paliperidone palmitate or placebo during the
15-month double-blind relapse prevention
phase. Subjects were considered to have
relapsed if they met any 1 or more of the
following conditions: psychiatric hospitalization
due to worsening of symptoms; other
significant interventions exercised to avoid
hospitalization for worsened symptoms such
as increasing the level of care or adding
additional medications; clinically significant
self-injury or violent behavior or suicidal or
homicidal ideation; significant worsening on
any of several key PANSS or on several other
PANSS measures, or on the CGI-S-SCA. The
primary efficacy outcome measure was the
comparison of relapse risk for psychotic and/or
mood symptoms while treated with
paliperidone palmitate, compared with
placebo; a key secondary objective was
comparison of the subject functional status, as
measured by the Personal and Social
Performance scale (PSP) [22].
There were 667 subjects who enrolled and
received at least one dose of medication in the
open-label phase; 334 were randomized 1:1 in
thedouble-blindphase topaliperidonepalmitate
or placebo injections. In thedouble-blindperiod,
the most commonly used dose of paliperidone
palmitate was 156 mg (47.0%), followed by
234 mg (38.4%), 117 mg (9.8%), and 78 mg
(4.9%). 15.2% of those randomized to
paliperidone palmitate relapsed, as compared
with 33.5% of those receiving placebo (hazard
ratio 2.49 times greater for placebo, 95%
confidence interval 1.55–3.99, P\0.001;
number needed to treat 6). For those receiving
adjunctive mood stabilizers or antidepressants,
the relapse risk was 2.03 times for those on
placebo compared with paliperidone; for those
not receiving adjunctive mood stabilizers or
antidepressants, the relapse risk was 3.38 times
for those on placebo compared with
paliperidone. Overall, paliperidone palmitate
was superior to placebo in maintaining
functioning measured by the PSP scale
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(P = 0.014, mixed-model repeated measures).
Significant improvements were also found at
study endpoint for HAM-D-21, YMRS, PANSS,
and CGI-S-SCA total scores for the paliperidone
group, compared with the placebo group.
TOLERABILITY OF PALIPERIDONE
FOR SCHIZOAFFECTIVE DISORDER
Tolerability of Paliperidone ER
for Schizoaffective Disorder
The most common adverse events reported in
subjects in the paliperidone ER for
schizoaffective disorder registration trials
(C5.0% and 29 placebo) were tremor (8.1% vs.
3.5% with placebo, number needed to harm
[NNH] 22), hypertonia (5.5% vs. 2.0% with
placebo, NNH 29), dyspepsia (5.5% vs. 2.5%
with placebo, NNH 34), and somnolence (5.2%
vs. 2.0% with placebo, NNH 32). For both
paliperidone ER and placebo treatment groups,
7% of subjects discontinued treatment due to
adverse events. For both males and females,
treatment with paliperidone ER was associated
with increases in serum prolactin levels.
Tolerability and Safety of Paliperidone
Palmitate for Schizoaffective Disorder
Interpreting differences in tolerability outcomes
versus placebo in the randomized phase is
complicated because subjects with tolerability
problems may have dropped out during the
prior open-label treatment phase. In the
paliperidone palmitate relapse prevention
study, 28.2% of the placebo group
discontinued treatment during the
double-blind phase, compared with 23.8% of
those in the paliperidone group. Higher rates of
subjects discontinued because of withdrawal of
consent and being lost to follow-up in the
control groups, but 5.5% of subjects in the
paliperidone group discontinued due to an
adverse event, as opposed to 1.8% on placebo
(NNH 27). There were 2 deaths in the
paliperidone group during the double-blind
phase, as well, one by overdose of sleeping
medication and one due to coronary artery
disease, neither judged by the investigator as
caused by the investigational product.
The common (C5%) treatment-emergent
adverse events (TEAEs) reported more
frequently in the paliperidone group than in
the placebo group were: weight increased (8.5%
paliperidone, 4.7% placebo, NNH 27),
nasopharyngitis (5.5% paliperidone, 3.5%
placebo, NNH 50), and headache (5.5%
paliperidone, 3.5% placebo, NNH 50).
Extrapyramidal symptom-related TEAEs were
reported in 8.5% of the paliperidone group,
compared with 7.1% of the placebo group
(NNH 72). Prolactin-related TEAEs occurred in
13.9% of women in the paliperidone group,
compared with 5.8% of women in the placebo
group (NNH 13). Thirteen percent of
paliperidone-treated compared with only 6% of
placebo-treated subjects gained C7% of their
weight during the study (NNH 15), although
there was only minimal mean weight change
reported for both groups.
PLACE IN THERAPY: AN OVERVIEW
OF OTHER TREATMENTS
COMMONLY USED TO TREAT SA
DISORDER
Paliperidone palmitate has joined the limited
ranks of LAI antipsychotic formulations
available. In the US, other available
alternatives include fluphenazine decanoate,
haloperidol decanoate, aripiprazole (trade
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name Abilify Maintena; Otsuka Pharmaceutical
Company), risperidone (trade name Risperdal
Consta; Janssen) and olanzapine pamoate
(trade name Zyprexa Relprevv; Eli Lilly and
Company); other options are available outside
of the US. These other LAIs do not have a
specific indication for schizoaffective disorder,
although in clinical practice they are commonly
used for this indication, and it would appear
likely that antipsychotics effective for
schizophrenia would generally be effective for
schizoaffective disorder. Fluphenazine and
haloperidol are first-generation antipsychotics,
and although they are much less expensive,
may be more prone to cause extrapyramidal side
effects.
Of the second-generation antipsychotics,
risperidone appears somewhat more likely to
cause extrapyramidal side effects, and its
pharmacokinetic properties are not conducive
to monthly maintenance injections for most; it
also requires a period of initial oral
supplementation. Olanzapine pamoate has
been associated with severe sedation as a rare
but serious adverse reaction (post-injection
delirium sedation syndrome), and patients
must be observed for at least three hours after
injections in a registered facility with ready
access to emergency services [23]. One US
multisite, double-blind randomized
head-to-head comparison of haloperidol
decanoate to paliperidone palmitate in the
maintenance treatment of patients diagnosed
with schizophrenia or schizoaffective disorder
found no significant difference in the rate of
efficacy failure, and on the safety side reported
more weight gain and increased prolactin levels
in those on paliperidone palmitate, and more
akathisia in patients taking haloperidol
decanoate [24]. Aripiprazole, a D2 partial
agonist, is also available as a long-acting
injection, and an application of a formulation
from a different manufacturer is currently under
FDA review [25].
The issue of acquisition cost is a significant
one, as access to the much more expensive,
branded drugs is being affected by their needing
to be reviewed for prior authorization by most
pharmacy benefit managers. Of note is the
recently published clinical trial of a new
three-month formulation of paliperidone
palmitate [trade name Invega Trinza], used
successfully to prevent relapse in subjects with
schizophrenia, which the FDA has recently
approved for this indication.
(ClinicalTrials.gov identifier, NCT01529515)
[26, 27]. A three-month LAI formulation is a
very welcome therapeutic option for
non-adherent patients and their families and
treatment providers. Choosing an appropriate
LAI involves a number of pertinent
considerations, including knowledge of the
particular pharmacokinetics of the relevant
options and likely adverse events [28].
Guidance regarding how to best switch
antipsychotic medications has received only
limited attention, particularly for
schizoaffective disorder [29].
SUMMARY AND CONCLUSIONS:
BALANCING EFFICACY AND SAFETY
Paliperidone appears to be an effective modality
not only in the acute treatment of
schizoaffective disorder, but in preventing
relapse for those with this disorder, the latter
as evidenced in a 15-month maintenance of
effect trial of paliperidone palmitate as both a
monotherapy and as adjunct to oral mood
stabilizers or antidepressant medication.
Paliperidone is generally tolerated well,
although its propensity to increase prolactin
levels and cause extrapyramidal side effects and
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weight gain should be recognized. It can be used
with adjunctive mood stabilizers or
antidepressants, if they appear indicated.
Favorable characteristics include its not
requiring an initial oral supplementation
period because of favorable pharmacokinetic
parameters, and not being significantly affected
by drug–drug interactions or CYP450 hepatic
enzyme poor- or rapid-metabolizer status,
decided advantages for some patients,
although dosage adjustments may be needed
for those with poor renal function. If the
three-month version is also effective for those
with schizoaffective disorder, this will prove a
considerable benefit in treating non-adherent
individuals or those who elect to receive a
medication 4 times a year for convenience.
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